MOCRAVIMOD DOES NOT HAVE A CLINICALLY RELEVANT DRUG-DRUG INTERACTION WITH STRONG CYP3A4 INHIBITOR ITRACONAZOLE

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [1 ]
Kueenburg, Elisabeth [1 ]
机构：
[1] Priothera SAS, St Louis, France
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P768
引用
收藏
页码：740 / 741
页数：2
相关论文
共 50 条
  • [1] Drug-drug interaction between tamsulosin and diltiazem, a moderate CYP3A4 inhibitor
    Byeon, Ji-Yeong
    Park, Jung-In
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E238 - E239
  • [2] DRUG-DRUG INTERACTION STUDY OF INCB050465 WITH CYP3A4 INHIBITOR ITRACONAZOLE AND INDUCER RIFAMPIN IN HEALTHY VOLUNTEERS.
    Li, J.
    Rockich, K.
    Epstein, N.
    Ji, T.
    Chen, X.
    Yeleswaram, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S45 - S45
  • [3] AN OPEN-LABEL STUDY TO EVALUATE THE DRUG-DRUG INTERACTION EFFECT OF ITRACONAZOLE, A STRONG CYP3A4 AND P-GP INHIBITOR, ON THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS.
    Cardona, P.
    Hutton, S.
    Purkis, J.
    Mather, O.
    Dutta, S.
    Houk, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S12 - S12
  • [4] Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study
    Hu, Xiaolei
    Hsieh, Chih-Yi
    Zhang, Yanxin
    Liu, Wanli
    Xu, Sumei
    Cai, Sui Xiong
    Liu, Lan
    Zhang, Ming
    Shi, Huiyan
    Zhang, Hongxia
    Liu, Ping
    Li, Xiaomin
    Xu, Pingsheng
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (06) : 1767 - 1779
  • [5] The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4
    Wang, Xianming
    Zhang, Xiang
    Huang, Xinhui
    Li, Yuntong
    Wu, Mengchao
    Liu, Jingfeng
    XENOBIOTICA, 2016, 46 (07) : 651 - 658
  • [6] The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan
    Antila, S
    Honkanen, T
    Lehtonen, L
    Neuvonen, PJ
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1998, 36 (08) : 446 - 449
  • [7] CYP3A4 HUMANIZED MOUSE; A MODEL TO STUDY CYP3A4-MEDIATED DRUG-DRUG INTERACTION POTENTIAL
    Rose, Anne
    Xu, Carrie
    Johnghar, Susan
    Behnia, Kamelia
    DRUG METABOLISM REVIEWS, 2012, 44 : 76 - 77
  • [8] Homotropic and heterotropic cooperativity of CYP3A4 and drug-drug interactions
    Denisov, Ilia G.
    Frank, Daniel
    Grinkova, Yelena V.
    Sligar, Stephen G.
    FASEB JOURNAL, 2008, 22
  • [9] Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns
    Emoto, C.
    Iwasaki, K.
    XENOBIOTICA, 2006, 36 (2-3) : 219 - 233
  • [10] Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation
    Ren, Hong-can
    Sai, Yang
    Chen, Tao
    Zhang, Chun
    Tang, Lily
    Yang, Cheng-guang
    AAPS JOURNAL, 2021, 24 (01):
12345